
Merck’s Allergopharma opens €42m biopharmaceutical plant
pharmafile | March 7, 2017 | News story | Manufacturing and Production | Allergopharma, Merck
Allergopharma, a subsidiary of Germany’s Merck, has completed construction on its new €42 million biopharmaceutical facility and declared it open for business.
Work on the 6,000 square metre plant in Reinbek, near Hamburg, began in 2013, with Allergopharma stating that the new operation would aid its expansion into such as China. The company focuses on the development and production of immunotherapies for the treatment of allergies such as allergic rhinitis and allergic asthma.
Chief Operating Officer Simon Sturge stressed the significance of the new facility in a statement: ‘‘with this €42 million investment Merck is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy marketplace.”
CEO of Allergopharma Marco Linari added: “From a technology point of view, the new biopharmaceutical production is a quantum leap. It means an increase in supply safety for patients, a further improvement of product quality and future innovations towards improving therapy.”
Matt Fellows
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






